Quality of life in the trastuzumab for gastric cancer trial

Oncologist. 2014 Jul;19(7):712-9. doi: 10.1634/theoncologist.2014-0058. Epub 2014 Jun 20.


Background: The Trastuzumab for Gastric Cancer phase III trial demonstrated that combining trastuzumab with chemotherapy significantly improved overall survival compared with chemotherapy alone in HER2-positive advanced gastric or gastroesophageal junction cancer. We report health-related quality of life (HRQoL) and quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) results from this trial.

Patients and methods: Patients were randomized to receive six cycles of chemotherapy given every 3 weeks (capecitabine or fluorouracil, plus cisplatin) either alone or combined with administration of trastuzumab every 3 weeks until disease progression. At each clinical visit, HRQoL was assessed using two European Organization for Research and Treatment of Cancer quality of life questionnaires, QLQ-C30 and QLQ-STO22. Q-TWiST methodology was applied retrospectively using the clinical data and utility coefficients.

Results: Trastuzumab plus chemotherapy prolonged time to 10% definitive deterioration in all QLQ-C30 and QLQ-STO22 scores, including QLQ-C30 global health status versus chemotherapy alone, from 6.4 months to 10.2 months. In addition, trastuzumab plus chemotherapy extended Q-TWiST by 2.42 months compared with chemotherapy alone.

Conclusion: Compared with chemotherapy alone, trastuzumab plus chemotherapy prolongs time to deterioration of HRQoL and increases quality-adjusted survival in patients with HER2-positive gastric or gastroesophageal junction cancer.


背景。使用曲妥珠单抗治疗胃癌的 III 期研究表明,与单纯化疗相比,曲妥珠单抗与化疗药物的联合使用可显著提高 HER2 阳性晚期胃癌或食管胃结合部癌患者的总生存期。本文报告了这项研究的健康相关生存质量 (HRQoL) 及生存质量校正后的无疾病症状无毒性生存期 (Q-TWiST) 结果。

患者与方法。患者被随机分为两组,分别接受单纯化疗(卡培他滨或氟尿嘧啶,联合顺铂,每 3 周一个周期,共 6 个周期)或化疗联合曲妥珠单抗(每 3 周一次)治疗,直至出现疾病进展。在每次临床就诊时,我们采用欧洲肿瘤研治组织的两份生存质量调查问卷 QLQ-C30 和 QLQ-STO22 对受试者进行 HRQoL 评估。Q-TWiST 的评估则采用回顾性方式依据临床数据和效用系数来进行。

结果。与单纯化疗相比,曲妥珠单抗与化疗药物的联合使用将所有 QLQ-C30 和 QLQ-STO22 评估指标的“至 10% 确定性下降时间”从 6.4 个月推迟到了 10.2 个月,其中包括 QLQ-C30 总体健康状态这一指标。此外,与单纯化疗相比,曲妥珠单抗与化疗的联合使用也将 Q-TWiST 延长了 2.42 个月。

结论。与单纯化疗相比,曲妥珠单抗与化疗的联合使用推迟了 HRQoL 的至下降时间,提高了 HER2 阳性胃癌或食管胃结合部癌患者的生存质量校正后生存期。

The Oncologist 2014;19:712–719

Trial registration: ClinicalTrials.gov NCT01041404.

Keywords: Chemotherapy; Gastric cancer; HER2; Quality of life; Trastuzumab.

Publication types

  • Clinical Trial, Phase III
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Capecitabine
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives
  • Fluorouracil / administration & dosage
  • Fluorouracil / adverse effects
  • Fluorouracil / analogs & derivatives
  • Humans
  • Quality of Life
  • Receptor, ErbB-2 / metabolism
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / enzymology
  • Surveys and Questionnaires
  • Trastuzumab


  • Antibodies, Monoclonal, Humanized
  • Deoxycytidine
  • Capecitabine
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab
  • Cisplatin
  • Fluorouracil

Associated data

  • ClinicalTrials.gov/NCT01041404